AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
December 10, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious...
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
November 14, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein...
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
November 13, 2024 07:00 ET
|
AC Immune SA
AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 05, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and...
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
September 17, 2024 07:00 ET
|
AC Immune SA
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical...
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
August 28, 2024 09:00 ET
|
AC Immune SA
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s...
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront...
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
July 31, 2024 08:30 ET
|
AC Immune SA
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small...
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
July 25, 2024 07:00 ET
|
AC Immune SA
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarterPhase 2b ReTain...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
July 16, 2024 07:00 ET
|
AC Immune SA
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s...